Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia
BACKGROUND AND AIMS: Ventilator-associated pneumonia (VAP) is one of the most common Intensive Care Unit (ICU)-acquired infection. The aim of this study was to compare the clinical outcome of continuous and intermittent administration of piperacillin-tazobactam by serial measurements of the Clinical Pulmonary Infection Score (CPIS).
SUBJECTS AND METHODS: Groups were designed as parallel and the study was designed as quasi-experimental and conducted at a semi-closed ICU between September 2008 and May 2010. Patients received 3.375 g (piperacillin 3 g/tazobactam 0.375 g) either through intermittent infusion every 6 h for 30 min [Intermittent Infusion (II) group; n = 30] or through continuous infusion every 8 h for 4 h [Continuous Infusion (CI) group; n = 31]. CPIS was used to assess the clinical diagnosis and outcome of VAP patients.
RESULTS: Sex, age, Acute Physiology and Chronic Health Evaluation II II score on ICU admission, diagnosis and underlying disease of VAP patients were not significantly different in the CI (n = 31) and II (n = 30) groups. Duration of mechanical ventilation, length of stay, total number of antibiotics used per patient and duration of piperacillin/tazobactam treatment were similar in both groups. Mortality rates of VAP patients were similar between both groups during hospitalization.
CONCLUSION: There was no significant difference in clinical outcomes of patients receiving piperacillin-tazobactam via CI or II when measured by serial CPIS score.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine - 16(2012), 3 vom: 01. Juli, Seite 141-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fahimi, Fanak [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 29.11.2012 Date Revised 17.03.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/0972-5229.102083 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM222967943 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM222967943 | ||
| 003 | DE-627 | ||
| 005 | 20231224055607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/0972-5229.102083 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0743.xml |
| 035 | |a (DE-627)NLM222967943 | ||
| 035 | |a (NLM)23188954 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fahimi, Fanak |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2012 | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND AND AIMS: Ventilator-associated pneumonia (VAP) is one of the most common Intensive Care Unit (ICU)-acquired infection. The aim of this study was to compare the clinical outcome of continuous and intermittent administration of piperacillin-tazobactam by serial measurements of the Clinical Pulmonary Infection Score (CPIS) | ||
| 520 | |a SUBJECTS AND METHODS: Groups were designed as parallel and the study was designed as quasi-experimental and conducted at a semi-closed ICU between September 2008 and May 2010. Patients received 3.375 g (piperacillin 3 g/tazobactam 0.375 g) either through intermittent infusion every 6 h for 30 min [Intermittent Infusion (II) group; n = 30] or through continuous infusion every 8 h for 4 h [Continuous Infusion (CI) group; n = 31]. CPIS was used to assess the clinical diagnosis and outcome of VAP patients | ||
| 520 | |a RESULTS: Sex, age, Acute Physiology and Chronic Health Evaluation II II score on ICU admission, diagnosis and underlying disease of VAP patients were not significantly different in the CI (n = 31) and II (n = 30) groups. Duration of mechanical ventilation, length of stay, total number of antibiotics used per patient and duration of piperacillin/tazobactam treatment were similar in both groups. Mortality rates of VAP patients were similar between both groups during hospitalization | ||
| 520 | |a CONCLUSION: There was no significant difference in clinical outcomes of patients receiving piperacillin-tazobactam via CI or II when measured by serial CPIS score | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Piperacillin | |
| 650 | 4 | |a tazobactam | |
| 650 | 4 | |a ventilator-associated pneumonia | |
| 700 | 1 | |a Ghafari, Somayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Jamaati, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Baniasadi, Shadi |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi, Arvin |e verfasserin |4 aut | |
| 700 | 1 | |a Akhzarmehr, Arnavaz |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemian, Seyed Mohammad Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine |d 2008 |g 16(2012), 3 vom: 01. Juli, Seite 141-7 |w (DE-627)NLM191247936 |x 0972-5229 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2012 |g number:3 |g day:01 |g month:07 |g pages:141-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/0972-5229.102083 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2012 |e 3 |b 01 |c 07 |h 141-7 | ||